BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 13, 2026
Home » Topics » Briefs » Regulatory actions

Regulatory actions
Regulatory actions RSS Feed RSS

Regulatory actions for July 12, 2022

July 12, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Anthos, Arcutis, Can-Fite, Iterum, Lipocine, Perrigo, Pfizer, SCG.
Read More

Regulatory actions for July 11, 2022

July 11, 2022
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Accelerate Diagnostics, Nyxoah.
Read More

Regulatory actions for July 11, 2022

July 11, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alimera, Horizon, MGC, Puma, Siga.
Read More

Regulatory actions for July 8, 2022

July 8, 2022
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Empowered Diagnostics.
Read More

Regulatory actions for July 8, 2022

July 8, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adverum, Annovis, Bausch + Lomb, Clovis, Diamedica, Innocare, Pfizer, Xortx.
Read More

Regulatory actions for July 7, 2022

July 7, 2022

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Arcoma, Renovia, Zsquare.


Read More

Regulatory actions for July 7, 2022

July 7, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascletis, Biogen, Chinook, Coherus, Junshi, Inflarx, Kazia, Olix, Pyramid, Roche, Sensorion, Takeda,  Titan, Turnstone.
Read More

Regulatory actions for July 6, 2022

July 6, 2022

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Inspire.


Read More

Regulatory actions for July 6, 2022

July 6, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amylyx, Aneurotech, Dyne, Hyloris, Novavax, Pfizer, Sanofi, Xbrane.
Read More

Regulatory actions for June 28-July 1, 2022

July 5, 2022
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: ABVC, Akeso, Ascentage, Astrazeneca, Daiichi Sankyo, Eli Lilly, Inflarx, Innovent Biologics, Jiangsu Recbio Technology, Kyowa Kirin, Pfizer, Prestige, Sinovac, Skye, Unibio Science, Valneva.
Read More
Previous 1 2 … 192 193 194 195 196 197 198 199 200 … 342 343 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2026.
  • Wainua autoinjector

    Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

    BioWorld
    News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
  • Silhouette with keyhole

    FENS 2026: Next-gen biologics take on brain disease

    BioWorld
    Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • NRF2 activators reported in Vailima Peninsula patent

    BioWorld Science
    Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing